Search

Displaying results 4081 - 4090 of 7603 in total
  1. Drug

    Droperidol

    go.drugbank.com/drugs/DB00450
    ApprovedInvestigationalVet approved

    It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)

  2. Drug

    Milbemycin oxime

    go.drugbank.com/drugs/DB11531
    ExperimentalVet approved

    Mixtures: Nexgard Spectra 9mg/2mg Chewable Tablets for Dogs 2-3.5kg, Nexgard Spectra 38mg/8mg Chewable Tablets for Dogs >7.5-15kg
  3. Drug

    Ordopidine

    go.drugbank.com/drugs/DB05196
    Investigational

    ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects … ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.

  4. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.

  5. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

  6. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. ...

  7. Drug

    Pimagedine

    go.drugbank.com/drugs/DB05383
    Investigational

    Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. … It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies.

  8. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.

  9. Drug

    VX-702

    go.drugbank.com/drugs/DB05470
    Investigational

    In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA. … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor.

  10. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.